Ashley L Garrett1, Stephen S Cha2, Elizabeth Wack3, Janis E Blair4. 1. Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA. 2. Department of and Biostatistics, Mayo Clinic, Scottsdale, AZ, USA. 3. Infectious Disease Consultants, Tucson, AZ, USA. 4. Division of Infectious Diseases, Mayo Clinic Hospital, 5777 E Mayo Blvd, Phoenix, AZ, 85054, USA. blair.janis@mayo.edu.
Abstract
BACKGROUND: Tumor necrosis factor α-inhibitors (TNFIs) have been associated with increased risk of certain fungal infections, including coccidioidomycosis. The optimal treatment approach to coccidioidomycosis in TNFI recipients is unknown. METHODS: We constructed an anonymous, voluntary survey for practicing pulmonary and infectious disease physicians in the state of Arizona regarding approach to TNFI patients with coccidioidomycosis. RESULTS: There is no current consensus on managing these patients. CONCLUSIONS: Further research is necessary to determine the optimal approach to TNFI recipients with coccidioidomycosis.
BACKGROUND: Tumor necrosis factor α-inhibitors (TNFIs) have been associated with increased risk of certain fungal infections, including coccidioidomycosis. The optimal treatment approach to coccidioidomycosis in TNFI recipients is unknown. METHODS: We constructed an anonymous, voluntary survey for practicing pulmonary and infectious disease physicians in the state of Arizona regarding approach to TNFI patients with coccidioidomycosis. RESULTS: There is no current consensus on managing these patients. CONCLUSIONS: Further research is necessary to determine the optimal approach to TNFI recipients with coccidioidomycosis.
Authors: Elizabeth Salt; Amanda T Wiggins; Mary Kay Rayens; Moises A Huaman; David Mannino; Philip Schwieterman; Scott A Merkley; Allison R Jones; Leslie J Crofford Journal: Arthritis Rheumatol Date: 2016-03 Impact factor: 10.995
Authors: John N Galgiani; Neil M Ampel; Janis E Blair; Antonino Catanzaro; Royce H Johnson; David A Stevens; Paul L Williams Journal: Clin Infect Dis Date: 2005-09-20 Impact factor: 9.079
Authors: Sara Taroumian; Susan L Knowles; Jeffrey R Lisse; James Yanes; Neil M Ampel; Austin Vaz; John N Galgiani; Susan E Hoover Journal: Arthritis Care Res (Hoboken) Date: 2012-12 Impact factor: 4.794
Authors: Daniel R Roach; Andrew G D Bean; Caroline Demangel; Malcolm P France; Helen Briscoe; Warwick J Britton Journal: J Immunol Date: 2002-05-01 Impact factor: 5.422
Authors: Laurie Bergstrom; David E Yocum; Neil M Ampel; Isidro Villanueva; Jeffrey Lisse; Oscar Gluck; John Tesser; James Posever; Margaret Miller; Julio Araujo; Dana M Kageyama; Martin Berry; Linda Karl; Christianne M Yung Journal: Arthritis Rheum Date: 2004-06
Authors: Janis E Blair; Yu-Hui H Chang; Meng-Ru Cheng; Laszlo T Vaszar; Holenarasipur R Vikram; Robert Orenstein; Shimon Kusne; Stanford Ho; Maria T Seville; James M Parish Journal: Emerg Infect Dis Date: 2014-06 Impact factor: 6.883